Cost should factor into breast cancer screening decisions for women in their 40s

Cost should factor into breast cancer screening decisions for women in their 40s

John R. Fischer, Senior Reporter | March 25, 2020
Women's Health
Few studies on the benefits of breast cancer screening for women in their 40s incorporate cost as a factor.
Women in their 40s who undergo breast cancer screenings could be dealt hefty charges depending on what part of the U.S. their exam is conducted in, says a Yale-led study.

Researchers at the Ivy league college, along with experts at the University of Oslo and New York University found variations in screening costs among different states, ranging from as low as $151 in some regions to $751 in others. The findings could potentially help make cost more relevant in decisions on whether to undergo screening before, or delay screening until at least the age of 50.

“This has been seen in other areas of healthcare as well,” senior author Dr. Cary Gross, Yale professor of medicine and a member of the Yale Cancer Center, told HCB News. “Providers simply command larger fees in some areas than in others, even for the same services. Another factor that can lead to differences in costs is that in some areas, 3D mammograms are more common (and these are more expensive) while in other areas, the traditional 2D mammograms are more common.”

Servicing GE/Siemens Nuclear Medicine equipment with OEM trained engineers

Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.

The most common type of cancer affecting U.S. women, breast cancer, is the fourth leading cause of cancer-related deaths in the country. Most guidelines recommend that average-risk women undergo mammography screenings between ages 50 and 74. While many experts debate the benefits and risks of screening women under 50, few studies on the matter have incorporated associated costs as a factor.

The team decided to address lack of cost assessment in such decisions through a trial using records from more than two million women between 40 and 49. Records were pulled from the Blue Cross Blue Shields Axis, a commercial claims database accessed via a secure portal.

Of women in their 40s, 41.2% underwent standard mammography screenings, while 24.1% opted for 2D mammography and 17.2% chose DBT. The mean costs of breast cancer screening was $353 per beneficiary, with total costs depending on region ranging from $151 to $751. The most expensive took place in areas of California, New York, Alaska, Wisconsin, and Michigan. The lowest were in regions of Alabama and Arkansas.

The aim of the study, according to Gross, is to help produce accurate insight that will enable providers to make more informed decisions around breast cancer screening, as well as open up more opportunities for research on the subject. He adds that one way of ensuring patients have access to affordable screening is to communicate with mammography practices about where they prescribe screening, and what the costs would be, should additional testing be required.

“There is so much variation across providers,” he said. “I'd suggest asking the mammogram facilities where they are considering getting a mammogram — and also, if there is a need for additional testing after a mammogram (i.e., if the mammogram showed an abnormality and there is a need for a biopsy), its important to ask about whether the facility and doctor are part of your insurance network, and if you'd have to pay any "out of network" fees.”

Gross and his team plan to investigate drivers behind cost variation across different geographic regions to better understand the role that variation across mammography facilities plays in overall regional variation.

Data for this project was supplied through a collaboration between Yale University and Blue Cross Blue Shield Association (BCBSA). The study was funded by a grant from the American Cancer Society.

The findings were published in JAMA Internal Medicine.

You Must Be Logged In To Post A Comment